Ocumension Therapeutics announced that OT-502 (dexamethasone implant), a new drug for the treatment of postoperative inflammation indication, has completed the enrollment of a total of 263 patients for the real-world study in Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, the People's Republic of China, among which 113 patients were in the experimental group and 150 patients were in the control group. OT-502 (dexamethasone implant) is a single-dose, sustained-release solution of dexamethasone, a corticosteroid, for the treatment of postoperative inflammation. To date, OT-502 is the first and only single-dose, sustained-release intracameral steroid for the treatment of postoperative inflammation that was approved by the United States Food and Drug Administration.

The Group is developing OT-502 as a potential first-in-class treatment for postoperative inflammation associated with cataract surgery in China.